ArticleFrontiers in neurology2019
Effects of CBD-Enriched
Article in Frontiers in neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 3 syntheses or guidelines pooled it, 116 citations in OpenAlex.
- Alterations of the endocannabinoid system in autism spectrum disorder: a systematic review and meta-analysis.European archives of psychiatry and clinical neuroscience · 2025Pooled it
- Efficacy of cannabinoids in neurodevelopmental and neuropsychiatric disorders among children and adolescents: a systematic review.European child & adolescent psychiatry · 2024Pooled it
- Cannabis and cannabinoid use in autism spectrum disorder: a systematic review.Trends in psychiatry and psychotherapy · 2022Pooled it
- Cannabidiol blood metabolite levels after cannabidiol treatment are associated with broadband EEG changes and improvements in visuomotor and non-verbal cognitive abilities in boys with autism requiring higher levels of support.Translational psychiatry · 2026Trial
- Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: randomized, double-blind, and placebo-controlled clinical trial.Trends in psychiatry and psychotherapy · 2024Trial
- Children and adolescents with ASD treated with CBD-rich cannabis exhibit significant improvements particularly in social symptoms: an open label study.Translational psychiatry · 2022Trial
- Cannabinoid treatment for autism: a proof-of-concept randomized trial.Molecular autism · 2021Trial
- Psychiatric effects of cannabidiol, cannabinol, and tetrahydrocannabinol: A narrative review of clinical evidence and risk profiles.PCN reports : psychiatry and clinical neurosciences · 2026Review
- Cannabidiol at the crossroads: panacea, placebo, or problem?Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Review
- Cannabidiol blood metabolite levels after cannabidiol treatment are associated with broadband EEG changes and improvements in visuomotor and non-verbal cognitive abilities in boys with autism requiring higher levels of support.medRxiv : the preprint server for health sciences · 2025Article
- Acute effects of cannabis on core and co-occurring features associated with autism spectrum disorder in adults.Scientific reports · 2025Article
- Effects of Medical Cannabis Treatment for Autistic Children on Family Accommodation: An Open-Label Mixed-Methods Study.Children (Basel, Switzerland) · 2025Article
- Efficacy and Safety of Cannabinoids for Autism Spectrum Disorder: An Updated Systematic Review.Cureus · 2025Review
- Full-spectrum cannabis extracts for women with chronic pain syndromes: a real-life retrospective report of multi-symptomatic benefits after treatment with individually tailored dosage schemes.Frontiers in pharmacology · 2025Article
- Article
- Cannabidiol Supplements in Romania: Bridging the Gap Between Marketed Claims and Clinical Reality.Pharmacy (Basel, Switzerland) · 2024Article
- Pharmacotherapy for the core symptoms of autism spectrum disorder.Journal of Zhejiang University. Science. B · 2024Review
- Evaluation of the Efficacy of a Full-Spectrum Low-THCBiomolecules · 2024Article
- Endocannabinoid System Changes throughout Life: Implications and Therapeutic Potential for Autism, ADHD, and Alzheimer's Disease.Brain sciences · 2024Review
- Clinical and Family Implications of Cannabidiol (CBD)-Dominant Full-Spectrum Phytocannabinoid Extract in Children and Adolescents with Moderate to Severe Non-Syndromic Autism Spectrum Disorder (ASD): An Observational Study on Neurobehavioral Management.Pharmaceuticals (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autism Spectrum Disorders comprise conditions that may affect cognitive development, motor skills, social interaction, communication, and behavior. This set of functional deficits often results in lack of independence for the diagnosed individuals, and severe distress for patients, families, and caregivers. There is a mounting body of evidence indicating the effectiveness of pure cannabidiol (CBD) and CBD-enriched
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.